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Highlights:27
1. TMS was used to explore GABA-mediated inhibition in IGE28
2. Post-synaptic GABAB inhibition (LICI) was normal, but pre-synaptic LICF reduced29
3. GABAA inhibition (SICI) was reduced in untreated but not treated IGE30
4. When tested during GABAB inhibition, the SICI protocol was excitatory31
5. During ongoing GABAB inhibition, GABAA activation may be excitatory32
33
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Abstract33
Purpose: Impaired GABAergic inhibition has been implicated in the pathophysiology of 34
epilepsy. The possibility of a paradoxical excitatory effect of GABA in epilepsy has been 35
suggested, but has not been investigated in vivo. We investigated pre- and post-synaptic 36
GABAergic mechanisms in patients with idiopathic generalised epilepsy (IGE).37
Methods: In 10 patients and 12 control subjects we explored short- and long-interval 38
intracortical inhibition (SICI, LICI; post-synaptic GABAA and GABAB-mediated 39
respectively) and long-interval intracortical facilitation (LICF; pre-synaptic disinhibition) 40
using transcranial magnetic stimulation. 41
Results: While post-synaptic GABAB-mediated inhibition was unchanged in IGE (p=0.09), 42
LICF was reduced compared to controls (controls: 141±17% of baseline; untreated patients: 43
107±12%, p=0.2; treated patients: 79±10%, p=0.003). GABAA-mediated inhibition was 44
reduced in untreated patients (response amplitude 56±4% of baseline vs. 26±6% in controls, 45
p=0.004) and normalised with treatment (37±12%, p=0.5 vs. controls). When measured 46
during LICI, GABAA-mediated inhibition became excitatory in untreated IGE (response 47
amplitude 120±10% of baseline, p=0.017), but not in treated patients.48
Conclusions: Pre- and post-synaptic GABA-mediated inhibitory mechanisms are altered in 49
IGE. The findings lend in vivo support to evidence from experimental models and in vitro50
studies of human epileptic brain tissue that GABA may have a paradoxical excitatory role in 51
ictogenesis.52
Keywords: transcranial magnetic stimulation, epilepsy, cortical excitability, GABA, 53
disinhibition54
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Abbreviations:55
AED: anti-epileptic drug56
AEDNO: IGE not on AEDs (subject group)57
AEDON: IGE on AEDs (subject group)58
CS: conditioning stimulus59
EEG: electroencephalography60
EMG: electromyography61
FDI: first dorsal interosseous (muscle)62
GABAR: GABA receptor63
GABAAR: GABAA receptor64
GABABR: GABAB receptor65
I1mV: intensity needed to evoke a MEP of 1mV amplitude66
IGE: idiopathic generalised epilepsy67
ISI: inter-stimulus interval68
IPSP: inhibitory post-synaptic potential69
JME: juvenile myoclonic epilepsy70
KCC2: K+/Cl- cotransporter 271
LCD: late cortical disinhibition72
LICF: long-interval intracortical facilitation 73
LICI: long-interval intracortical inhibition74
MEP: motor evoked potential75
NKCC1: Na+/K+/2Cl- cotransporter 176
PS: priming stimulus77
RMT: resting motor threshold78
SICI: short-interval intracortical inhibition79
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TLE: temporal lobe epilepsy80
TMS: transcranial magnetic stimulation81
TS: test stimulus82
TS*: adjusted test stimulus83
84
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Introduction84
Epilepsy is characterised by neuronal hyperexcitability and hypersynchronicity which 85
manifests as recurrent seizures [1-2]. The pathophysiological processes underlying epilepsy 86
in its various forms remain incompletely understood (for reviews, see Engelborghs et al. [1]87
and McCormick and Contreras [2]) but an imbalance between excitatory and inhibitory 88
neuronal inputs is usually implicated. Critical to understanding the pathophysiology of 89
epileptogenesis and ictogenesis are abnormalities in synaptic transmission, and in particular 90
in the activity of GABAergic synaptic networks [2-5]. An improved understanding of in vivo91
synaptic function in epilepsy may inform diagnosis and clinical management.92
93
Within the central nervous system, GABAergic activity can regulate neuronal firing, 94
synchronicity and network oscillations [6]. At a cellular level, activation of post-synaptic 95
GABA receptors results in rapid transient (GABAAR-mediated) and longer-lasting 96
(GABABR-mediated) inhibitory post-synaptic potentials that can modulate or gate firing of 97
the post-synaptic neuron [7-9]. Pre-synaptic GABABRs remain active for longer than post-98
synaptic GABABRs, and regulate (reduce) further GABA release by inhibiting Ca
2+ influx,99
resulting in disinhibition [8, 10-11].100
101
In human motor cortex, the activation of GABARs can be measured with TMS using paired-102
pulse stimulation. SICI occurs when a sub-threshold conditioning pulse is delivered ~2-6ms 103
before a supra-threshold test pulse; the conditioning pulse elicits a GABAAR-mediated IPSP 104
and thereby reduces the amplitude of the MEP to the test pulse [12-13] . The ratio of the 105
amplitude of the conditioned MEP to the MEP for the test pulse alone can be used as an index 106
of GABAAR activation. A supra-threshold conditioning pulse results in activation of post-107
synaptic GABABRs, reducing test MEP amplitudes for conditioned-test ISIs of up to ~150ms 108
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(LICI) [14-16]. Pre-synaptic GABABRs activated by the conditioning pulse limit further 109
GABA release, and as they remain active for longer than post-synaptic GABABRs a period 110
arises beyond LICI when disinhibition dominates (LCD), and during which MEP amplitude 111
is increased (LICF) and SICI reduced [17-19].112
113
As pre- and post-synaptic GABARs can exert widespread influence over neuronal firing, 114
their dysfunction has been implicated in the processes of epileptogenesis and ictogenesis [2, 115
4-5, 20]. Previous TMS studies in patients with untreated IGE have reported reduced levels of 116
SICI compared to non-epileptic control subjects [21-25], suggesting a state of cortical 117
hyperexcitability with altered (decreased) cortical GABAA activity. Normal levels of SICI 118
have been consistently reported in patients with IGE who are well controlled on AED therapy 119
[21-25], apart from those with JME in whom SICI may [23, 26] or may not [27-28] return to 120
normal levels. The effect of IGE on LICI is not certain. Although not yet explored in human 121
IGE in vivo, impaired GABABR-mediated auto-inhibition has been demonstrated in in vitro122
studies of human brain tissue obtained from patients undergoing surgery for pharmaco-123
resistant temporal lobe epilepsy [10, 29]. While GABA mediates cortical inhibition and 124
disinhibition in adults, it is known to have excitatory effects early in development [30]. An 125
excitatory role for GABA in epilepsy has also been suggested on the basis of findings in 126
animal models and surgically resected human brain tissue [31-33].127
128
In the present study we used TMS to compare the strengths of short- and long-interval 129
intracortical inhibition and disinhibition in the motor cortex in patients with treated and 130
untreated IGE and in controls.131
132
Methods133
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Subjects134
Ten patients diagnosed with IGE (16-37 years of age, mean 23 years; 4 male, all right hand 135
dominant) were recruited from the Royal Perth Hospital First Seizure Clinic and from a 136
private epilepsy clinic. The diagnosis of IGE was made by an epileptologist (JWD, NDL or 137
PLS) on the basis of clinical assessment and EEG. Patients were divided into two groups 138
according to whether or not they were currently being treated with an AED (not on treatment: 139
AEDNO, on treatment: AEDON). Further patient details are presented in Table 1. Patients 140
taking multiple AEDs were not recruited. Four patients underwent repeat studies (at least two 141
weeks apart) after commencing (patients #1, #2 and #4) or ceasing (patients #5) AED 142
treatment as part of their prescribed epilepsy management. In total, seven sets of 143
measurements (three unique, four crossover) were obtained from patients off treatment, and 144
seven from patients on AED treatment (three unique, four crossover). Apart from patient #6, 145
all patients were seizure-free for at least 3 months following testing. Twelve healthy 146
individuals (19-32 years of age, mean 23 years; nine male, all right hand dominant) without a 147
history of epilepsy in first-degree relatives were recruited as a control group. Approval for the 148
clinical arm of the study was obtained from the Royal Perth Hospital Human Ethics 149
Committee, and University of Western Australia Human Research Ethics Committee granted 150
approval for control measurements. All participants provided written informed consent 151
according to the Declaration of Helsinki.152
153
Testing was performed at 9 AM, after a minimum of seven hours uninterrupted sleep the 154
night before. Participants abstained from alcohol in the 24 hours prior to testing and from 155
stimulant drinks (e.g. coffee, ‘energy drinks’) on the day of testing. The IGE group were 156
tested at least one week after their last generalised tonic-clonic seizure, and at least 24 hours 157
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after any other clinical seizure type. No participants were taking medications known to alter 158
seizure threshold (other than a single AED).159
160
TMS161
MEPs were recorded from the right FDI by surface EMG (sample rate 10kHz, amplification 162
x500, filtering 0.02–20kHz). TMS was delivered through a 7cm figure-of-eight coil 163
connected to three magnetic stimulators (Magstim 2002; Magstim Co., UK) linked through a 164
custom-built device. The coil was held tangential to the head and positioned in the 165
parasagittal plane at the optimal site for activation of the right FDI (determined from initial 166
exploration over a 1cm grid). Stimuli were delivered at 0.2Hz with the FDI relaxed, and 167
peak-peak MEP amplitude was measured. RMT was determined according to the Rossini-168
Rothwell criterion [34]. As recommended by safety guidelines, in all IGE subjects surface 169
EMG of the right deltoid muscle was monitored so as to detect intracortical spread of 170
excitation [35], and a neurologist (PLS) was present for all testing. No adverse events 171
occurred during testing.172
173
LICI/LICF174
LICI and LICF curves were generated using paired-pulse TMS. The single-pulse TMS 175
intensity needed to evoke a MEP of 1mV amplitude was first determined (I1mV), and both 176
stimuli in the paired-pulse were set to this intensity. The first pulse in a pair was designated 177
the priming stimulus and the second pulse the test stimulus (Figure 1). Paired-pulses were 178
delivered at 14 ISIs spaced so as to encompass the periods of LICI and LICF (100, 150, 170, 179
180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 350ms). ISIs were pseudo-randomised and 180
divided into four blocks, with eight stimuli for each ISI. At each ISI the mean TS-MEP 181
amplitude was calculated as a percentage of the mean PS-MEP. The ISIs corresponding to 182
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each subject’s greatest LICI and LICF were used in the triple-pulse SICI measurements 183
(SICILICI and SICILICF). In participants with IGE who did not show LICF, the ISI with 184
greatest PS-TS amplitude was used to evaluate SICILICF.185
186
SICI187
Triple-pulse TMS was used to measure SICI during LICI and LICF (Figure 1). A supra-188
threshold PS (at I1mV) was followed by a paired-pulse stimulus designed to elicit SICI, 189
consisting of a sub-threshold conditioning stimulus followed 2ms later by a supra-threshold 190
test stimulus (TS*) that was intensity-adjusted so as to give a MEP of 1mV in the presence of 191
LICI or LICF. The CS was delivered at three intensities: 0.7, 0.8 and 0.9 RMT. An ISI of 2ms 192
was chosen to avoid contamination of SICI by SICF [36]. Unprimed SICI was measured in 193
the absence of a PS, with TS at I1mV, and calculated from the ratio (expressed as a percentage) 194
of mean conditioned MEP amplitude (10 stimuli) to mean unconditioned test MEP amplitude 195
(10 stimuli). SICILICI and SICILICF were measured in the presence of a PS, and calculated 196
from mean conditioned TS* MEP amplitude to mean unconditioned TS* amplitude (10 197
stimuli). Stimuli were delivered in blocks of 40 for each of unprimed SICI, SICILICI and 198
SICILICF, comprised of 10 conditioned stimuli at each level of RMT and 10 unconditioned 199
stimuli, interspersed pseudo-randomly. 200
201
Data analysis202
Data was compared between Controls, AEDNO and AEDON. All data are expressed as mean ± 203
standard deviation.204
LICI/LICF: Mixed model analysis with random individual effects was used to compare 205
responses between groups, and to compare each group’s responses to baseline. Data was log 206
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transformed where required to better approximate normality for inference purposes.207
Adjustment for possible differences in baseline values did not alter results.208
SICI: Mixed model repeated measures analysis was performed with factors GROUP and209
RMT for each CONDITION (unprimed SICI, SICILICI, SICILICF). Responses were compared 210
between groups, and within each group responses were compared to baseline for each 211
condition. Adjustment for possible differences in baseline values did not alter results.212
213
Results214
LICI and LICF215
RMT was similar between groups (p=0.496). There was no significant difference between 216
baseline MEP amplitudes for Controls (1.60±0.30mV), AEDNO (1.19±0.15mV) and AEDON217
(1.35±0.09mV; p=0.46).218
219
Figure 2A presents the LICI/LICF curves for each group. LICI was of similar magnitude in 220
all groups at ISI 100-150ms (p=0.09), with a significant overall reduction in MEP amplitude 221
compared to baseline (mean 46±8% of baseline, p<0.001). At longer ISIs (200-250ms) the 222
Control group demonstrated LICF as expected, with MEP amplitude significantly increased 223
compared to baseline (mean 141±17% of baseline, p=0.015) and peaking at 210ms (151±21%224
of baseline). At these longer ISIs there was no statistically significant difference in amplitude225
compared to baseline for AEDNO (107±12%, p=0.56), while for AEDON the amplitude was 226
reduced, but with marginal significance (79±10% of baseline, p=0.045). There were 227
significant differences at ISI 200-250ms when groups were compared: amplitude in AEDON228
was lower than both AEDNO (p<0.001) and Controls (p=0.003), while those for AEDNO and 229
Controls were not significantly different to each other (p=0.2). Stratifying AEDON according 230
to specific AEDs (Figure 2B) suggests that the difference observed between AEDON and 231
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AEDNO may be due to lamotrigine. LICI and LICF values for patients tested both on and off 232
AED treatment are listed in Table 2.233
234
SICI235
There was no significant difference in TS*-MEP amplitude between groups (mean 236
1.20±0.19mV; p=0.387), and no difference between MEPs for PS and TS* (p=0.245). The 237
ISI for SICILICI was 100ms in all participants, whereas the ISI for SICILICF varied between 238
180-250ms (median 210ms, interquartile range 203-230ms). Figure 3 shows SICI as a 239
function of CS intensity (0.7-0.9RMT) for each group (Control, AEDNO, AEDON) and each 240
stimulus combination (unprimed SICI, SICILICI, SICILICF). The mean values for unprimed 241
SICI, SICILICI, SICILICF in patients tested both on and off AED treatment are listed in Table 2.242
243
The overall mean unprimed SICI amplitude in the Control group was 29±4% of baseline. 244
Compared to this, SICI was significantly reduced during LICI (68±11% of baseline, 245
p<0.001), and remained reduced during LICF (53±7% of baseline, p<0.001). The difference 246
between SICILICI and SICILICF was also significant (p=0.02). 247
248
For the AEDON group, SICILICI (70±10% of baseline) and SICILICF (55±14% of baseline) were 249
significantly reduced compared to unprimed SICI (37±12% of baseline; p<0.001 and p=0.03,250
respectively). Unprimed SICI and SICILICI in AEDON were no different to the Control group 251
(p=0.500 and p=0.360, respectively).252
253
For the AEDNO group, unprimed SICI was reduced compared to AEDON and Controls at254
CS=0.8RMT (56±4% of baseline, p=0.001 and p=0.004, respectively) and 0.9RMT (52±8%255
of baseline, p=0.053 and p=0.01, respectively). SICILICI was 120±10% of baseline, indicating 256
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that CS increased TS* amplitude (p=0.017). This was significantly different to the Control 257
(p=0.007) and AEDON (p=0.009) groups, in which SICILICI was less than 100%. During LICF, 258
SICI in the AEDNO group was reduced compared to unprimed SICI (72±5% of baseline, 259
p=0.015). Figure 4 shows SICI MEP waveforms from a representative participant, 260
demonstrating the expected reduction in conditioned MEP amplitude without PS, but that 261
with PS the conditioned MEP is increased in amplitude relative to the unconditioned MEP. 262
263
There was no difference in SICILICF between any groups (p=0.980).264
265
Discussion266
The present study demonstrates significant differences in cortical inhibition between 267
individuals with IGE and healthy control subjects. Although LICI was unchanged in IGE, 268
there was no evidence for the post-LICI period of facilitation (LICF) that is present in healthy 269
individuals. The strength of SICI was also reduced, and when measured during LICI, the 270
SICI protocol elicited a paradoxical excitatory rather than an inhibitory response in untreated 271
epileptics. Treatment with AEDs was associated with restoration of normal levels of SICI. 272
These findings point to altered function of GABAergic inhibition in epilepsy, and suggest273
that under some circumstances GABA may have an excitatory rather than an inhibitory action 274
in the cortex in IGE.275
276
The conventional GABA hypothesis of epilepsy suggests that “a reduction of GABAergic 277
inhibition results in epilepsy while an enhancement of GABAergic inhibition results in an 278
antiepileptic effect” [37]. In recent years this hypothesis has been challenged by reports of 279
GABAARs with excitatory effects, likely due to alterations in chloride homeostasis (for 280
reviews, see [4, 31-33, 38-40]). Activation of the GABAAR opens Cl
- channels allowing a281
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flow of ions down their electrochemical gradient. The direction of this gradient is set by the 282
neuronal membrane cotransporters NKCC1 (influx of ions) and KCC2 (efflux of ions) [41].283
In utero, relative over-expression of NKCC1 results in high intracellular Cl- concentration, 284
and thus opening of the GABAAR Cl
- channel results in a depolarising (outward) ion flow 285
[42-46]. In normal early human infant life the relative expression of NKCC1 and KCC2 286
reverses, with over-expression of KCC2, thereby lowering intracellular Cl- concentration 287
such that GABAAR activation induces hyperpolarisation [47-48]. In vitro studies of adult 288
human brain tissue resected for treatment of pharmaco-resistant TLE demonstrate 289
pathological over-expression of NKCC1 and under-expression of KCC2, in which case 290
activation of GABAARs may lead to Cl
- efflux and neuronal depolarisation [49-53]. These 291
same findings have also been reported in epileptogenic peritumoural adult human brain tissue292
[54], and in combination with data from animal models suggest a potentially 293
epileptogenic/ictogenic role for GABAARs in epilepsy [4, 41]. Recent studies have also 294
identified mutations affecting GABAergic signalling in some individuals with familial IGE, 295
including loss-of-function mutations in Cl- channels resulting in abnormally elevated 296
intracellular Cl- concentration [55-57].297
298
One possible explanation as to why SICILICI facilitated MEPs is that LICI may contribute to a 299
reversal of the chloride gradient. During LICI, the GABABR IPSP (which is mediated by K
+300
outflow [7, 58-59]) may reduce KCC2 activity (which depends on the K+ gradient to 301
transport Cl- out of the cell) and result in a temporarily higher intracellular Cl- concentration 302
[41, 60-63]. A sufficiently high concentration could lead to Cl- efflux when GABAARs are 303
activated, and therefore a depolarising response to SICI. Collapse of the Cl- gradient with 304
subsequent depolarising responses has been demonstrated in animal models of focal and 305
generalised epilepsy [64-66] and in adult (focal) epileptic human brain tissue [10, 29]. 306
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Changes in K+/Cl- dynamics are thought to contribute to ictal and inter-ictal activity in 307
epilepsy [4, 40, 67], and may underlie the process of ictogenesis by converting a negative 308
(inhibitory) feedback loop (pyramidal cell activation of inhibitory interneurons) into a 309
positive (excitatory) loop [41, 68-69].310
311
In keeping with our previous findings [19], in healthy individuals LICI at ISIs of 100-150ms 312
was followed by a period of intracortical facilitation (LICF) between 200-250ms, and 313
disinhibition (detectable as a reduction in SICI) was present throughout both of these periods. 314
This pattern was not observed in IGE, where LICF was absent in both treated and untreated 315
groups of patients, although disinhibition (as determined by SICILICF) was present albeit 316
weaker for AEDNO. A reduction in the strength (and possibly duration) of pre-synaptic317
GABABR activity has been demonstrated in surgically resected brain tissue from adults with 318
focal epilepsy [29], and this could explain the absence of LICF with weaker SICILICF in our 319
patients.320
321
Consistent with previous studies in IGE [21-25] and one study of patients with generalised 322
epilepsy secondary to GABAAR subunit mutation (conferring partial loss of function) [70],323
we found a reduction in the strength of unprimed SICI in untreated epilepsy patients 324
compared to healthy controls, and interpret this as evidence of impaired GABAAR function.325
While this was restored by AED treatment, the number of AEDs in relation to sample size 326
does not enable this restoration of GABAAR function to be interpreted pharmacologically. 327
However, in contrast to Badawy et al. [21-24, 71-72] we did not observe LICF in IGE. 328
Badaway et al. found no evidence of LICI in their healthy controls, whereas we found LICI in 329
both controls and IGE, suggesting that there may be an interrelationship between the presence 330
of LICI and LICF [19]. As LICI is a well-established phenomenon in healthy individuals, its 331
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the absence in the Badaway et al. control groups complicates comparison with the present 332
findings.333
334
The abnormalities in GABA-mediated measurements in the present study warrant further 335
investigation and may have clinical applications for the diagnosis and treatment of IGE. The 336
diagnosis of IGE is primarily clinical based on history and examination, with EEG performed 337
to support the diagnosis and aid in syndromal subclassification and prognostication [73].338
However, up to ~50% of individuals who present with a seizure will have a normal inter-ictal 339
EEG (which does not exclude the diagnosis of epilepsy) and in others the EEG may be 340
abnormal yet non-diagnostic [74-75]. In these individuals, if the history is not clearly 341
diagnostic of IGE then measurement of LICF and SICILICI may be a useful diagnostic 342
adjunct. 343
344
In conclusion, we investigated the relationship between pre-synaptic disinhibition and post-345
synaptic inhibition in the motor cortex of treated and untreated IGE, and find that, during the 346
period of post-synaptic inhibition, ac ivation of GABAARs may have excitatory effects. The 347
findings lend in vivo support to a growing body of evidence from experimental models and in 348
vitro studies of human epileptic brain tissue that GABA may have an excitatory role in 349
epilepsy. Coupled with alterations in disinhibition, the present findings point to a complex 350
modulation of pre- and post-synaptic GABAergic mechanisms in epilepsy. 351
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Figure Legends:356
Figure 1: Protocol diagram. TOP: LICI/LICF curves were generated from paired-pulse TMS, 357
made up of a supra-threshold PS followed by TS (1mV MEP) delivered 100-350ms later. 358
This curve was used to identify the timing of strongest LICI (?) and LICF(?) for each 359
individual. BOTTOM: Paired- and triple-pulse TMS was used to measure LICI, LICF, and 360
SICI during both LICI and LICF. LICI/LICF was calculated at each ISI from the amplitude 361
ratio of primed-to-unprimed TS. Unprimed SICI was calculated from the amplitude ratio of 362
unconditioned-to-conditioned TS at ISI 2ms. At the two post-PS intervals corresponding to 363
LICI and LICF, TS intensity was adjusted to restore MEP amplitude to 1mV (TS*) in the 364
presence of PS and SICI was then measured by delivering a CS prior to TS*.365
366
Figure 2: LICI/LICF curves: Mean paired-pulse (PS-TS) MEP amplitudes at each ISI, 367
expressed as a percentage of single-pulse baseline. Error bars represent standard error. (A) 368
All subject groups; (B) Subjects in AEDON only, according to specific AEDs. 369
370
Figure 3: SICI curves: Mean conditioned MEP amplitudes expressed as a percentage of 371
unconditioned amplitudes. Values <100% indicate inhibition (0% corresponds to complete 372
suppression of MEPs), and values >100% indicate a facilitatory response. Error bars 373
represent standard error.374
375
Figure 4: MEP waveforms (overlay of 3) from a representative IGE patient (Subject 1, 376
AEDNO). Without the priming stimulus (top row), conditioned MEP amplitude (CS-TS) is 377
reduced compared to unconditioned (TS) amplitude. Measurements made after a PS (during 378
LICI) show the conditioned MEP amplitude to be greater than for the unconditioned MEP.379
380
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Tables:381
Table 1: Demographics of patients with idiopathic generalised epilepsy382
Patient Gender Age AED
Months on 
current AED#
Epilepsy 
Syndrome
Inter-ictal 
EEG
Months since 
last seizure
AEDNO
1* F 16 - IGETCS GSW 3
2* M 22 - JME GSW 0.3
3 F 19 - IGETCS GSW 9
4* M 35 - JAE GSW 1
5* M 22 - IGETCS GSW 27
6 F 26 - JME GSW, PPR 0.25
7 F 37 - IGETCS GSW 14
AEDON
1* F 17 LTG 3 IGETCS GSW 7
2* M 22 VPA 0.5 JME GSW 1
4* M 36 VPA 8 JAE GSW 6
5* M 21 LTG 17 IGETCS GSW 24
8 M 18 VPA 10 IGETCS GSW 5
9 F 18 LTG 8 JAE GSW 36
10 F 18 LTG 10 JAE GSW 6
GSW: sporadic generalised spike and wave pattern, IGETCS: idiopathic generalised epilepsy 383
with tonic-clonic seizures, JAE: juvenile absence epilepsy, LTG: lamotrigine, PPR:384
photoparoxysmal response, VPA: sodium valproate. 385
* indicates subject tested both on and off AEDs386
# ‘current AED’ refers to both medication and dosage387
388
Table 2: LICI, LICF and SICI in subjects tested both on and off AED treatment389
LICI LICF Unprimed SICI SICILICI SICILICF
Patient Off On Off On Off On Off On Off On
1 53% 90% 148% 116% 35% 7% -15% 12% 25% 13%
2 51% 63% 157% 118% 70% 88% 30% 18% 36% 65%
4 3% 12% 117% 75% 46% 41% -28% 4% 35% 17%
5 1% 4% 65% 63% 44% 73% -60% # 43% -4%
LICI values correspond to ISI 100ms, and LICF values correspond to each subject’s peak 390
ISIs (as described under Methods). All SICI values are averaged across CS 0.7-0.9RMT.391
# unable to measure SICILICI as maximum stimulator output reached392
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Tables:612
Table 1: Demographics of patients with idiopathic generalised epilepsy613
Patient Gender Age AED
Months on 
current AED#
Epilepsy 
Syndrome
Inter-ictal 
EEG
Months since 
last seizure
AEDNO
1* F 16 - IGETCS GSW 3
2* M 22 - JME GSW 0.3
3 F 19 - IGETCS GSW 9
4* M 35 - JAE GSW 1
5* M 22 - IGETCS GSW 27
6 F 26 - JME GSW, PPR 0.25
7 F 37 - IGETCS GSW 14
AEDON
1* F 17 LTG 3 IGETCS GSW 7
2* M 22 VPA 0.5 JME GSW 1
4* M 36 VPA 8 JAE GSW 6
5* M 21 LTG 17 IGETCS GSW 24
8 M 18 VPA 10 IGETCS GSW 5
9 F 18 LTG 8 JAE GSW 36
10 F 18 LTG 10 JAE GSW 6
GSW: sporadic generalised spike and wave pattern, IGETCS: idiopathic generalised epilepsy 614
with tonic-clonic seizures, JAE: juvenile absence epilepsy, LTG: lamotrigine, PPR:615
photoparoxysmal response, VPA: sodium valproate. 616
* indicates subject tested both on and off AEDs617
# ‘current AED’ refers to both medication and dosage618
619
Table 2: LICI, LICF and SICI in subjects tested both on and off AED treatment620
LICI LICF Unprimed SICI SICILICI SICILICF
Patient Off On Off On Off On Off On Off On
1 53% 90% 148% 116% 35% 7% -15% 12% 25% 13%
2 51% 63% 157% 118% 70% 88% 30% 18% 36% 65%
4 3% 12% 117% 75% 46% 41% -28% 4% 35% 17%
5 1% 4% 65% 63% 44% 73% -60% # 43% -4%
LICI values correspond to ISI 100ms, and LICF values correspond to each subject’s peak 621
ISIs (as described under Methods). All SICI values are averaged across CS 0.7-0.9RMT.622
# unable to measure SICILICI as maximum stimulator output reached623
624
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